Mercer Global Advisors
SNOA icon

Mercer Global Advisors’s Sonoma Pharmaceuticals SNOA Stock Holding History

Mercer Global Advisors’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-361
Closed -$61K – 1190
2019
Q1 		$61K Buy
+361
New +$54.6K ﹤0.01% 1038

Other funds holding SNOA

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
RE
RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return

Mercer Global Advisors's SNOA Position: Q2 2019 in Review

Mercer Global Advisors sold out of Sonoma Pharmaceuticals (SNOA) in Q2 2019, closing a stake of 361 shares — an estimated $61K sold.

Mercer Global Advisors first reported a position in SNOA in Q1 2019 and held it in 1 quarter. The position peaked at $61K in Q1 2019. 13 funds tracked by Wall St. Rank hold SNOA as of Q2 2019.

  • Mercer Global Advisors reported no remaining Sonoma Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Mercer Global Advisors sold 361 Sonoma Pharmaceuticals shares in Q2 2019, an estimated $61K.
  • Mercer Global Advisors first reported a position in Sonoma Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Mercer Global Advisors's Sonoma Pharmaceuticals position peaked at $61K in Q1 2019.
  • 13 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q2 2019.

Based on Mercer Global Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.